person · Reporting owner
Scalzo Richard William
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC.CBIO · Entity 5255 | Chief Financial Officer | September 16, 2026 | September 18, 2026 |
| Dyne Therapeutics, Inc.DYN · Entity 3948 | SVP, Head of Finance & Admin. | March 11, 2025 | March 13, 2025 |
| Kaleido Biosciences, Inc.KLDO · Entity 129745 | Principal Accounting Officer | October 11, 2019 | October 15, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRESCENT BIOPHARMA, INC.
Report date September 16, 2026 · Filed September 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 19,730 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Sale · Disposed 568 · Balance 19,730 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
Dyne Therapeutics, Inc.
Report date March 11, 2025 · Filed March 13, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 122,330 |
Reported balance
After 2025-03-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-03-11 · Sale · Disposed 1,343 · Balance 122,330 F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F3: Includes 109,054 unvested RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.25 to $11.48, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4.
F3: Includes 109,054 unvested RSUs.
Kaleido Biosciences, Inc.
Report date October 11, 2019 · Filed October 15, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.28 · Expires 2028-08-15 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-11 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: 25% of this option vested and became exercisable on August 18, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.78 · Expires 2028-09-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2019-10-11 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F2: 25% of this option vested and became exercisable on September 5, 2019, with the remainder vesting in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option vested and became exercisable on August 18, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.
F2: 25% of this option vested and became exercisable on September 5, 2019, with the remainder vesting in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 3,429 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-024298 · ownership.xml · derivative · entry 6 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,311 Underlying: Common Stock · 3,429 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 3,429 | $27.50 | $94,297.50 |
DisclosureSEC source: 0000950170-24-024298 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,228 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $27.50 to $27.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Form 4. F1 · balance_after: Includes 118,605 unvested RSUs. Read SEC document |
| February 29, 2024 Filed Mar 2, 2024 02:37 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 3,429 | $1.03 | $3,531.87 |
DisclosureSEC source: 0000950170-24-024298 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,657 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 118,605 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-008061 · ownership.xml · derivative · entry 3 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,740 Underlying: Common Stock · 13,000 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,000 | $24.34 | $316,420.00 |
DisclosureSEC source: 0000950170-24-008061 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,228 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $24.00 to $25.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F1 · balance_after: Includes 124,213 unvested RSUs. Read SEC document |
| January 26, 2024 Filed Jan 27, 2024 00:47 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 13,000 | $1.03 | $13,390.00 |
DisclosureSEC source: 0000950170-24-008061 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 124,213 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock option (right to buy) · Derivative | 13,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0000950170-24-002277 · ownership.xml · derivative · entry 3 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,740 Underlying: Common Stock · 13,000 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 13,000 | $18.81 | $244,530.00 |
DisclosureSEC source: 0000950170-24-002277 · ownership.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,228 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.50 to $19.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4. F1 · balance_after: Includes 124,213 unvested RSUs. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 02:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 13,000 | $1.03 | $13,390.00 |
DisclosureSEC source: 0000950170-24-002277 · ownership.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · SVP, Head of Finance & Admin. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 137,228 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 124,213 unvested RSUs. Read SEC document |
| December 14, 2023 Filed Dec 14, 2023 21:59 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 2,376 | $12.02 | $28,559.52 |
DisclosureSEC source: 0001209191-23-058666 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 124,228 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 22:35 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,380 | $10.72 | $14,793.60 |
DisclosureSEC source: 0001209191-23-058332 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,604 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.72 to $10.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 124,213 unvested RSUs. Read SEC document |
| December 06, 2023 Filed Dec 6, 2023 23:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,872 | $12.01 | $22,482.72 |
DisclosureSEC source: 0001209191-23-057671 · doc4.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 127,984 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.04, inclusive. Read SEC document |
| December 04, 2023 Filed Dec 6, 2023 23:13 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 681 | $12.01 | $8,178.81 |
DisclosureSEC source: 0001209191-23-057671 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 129,856 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 11, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:35 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 34,946 | $0.00 Strike: $10.88 | $0.00 |
DisclosureSEC source: 0001209191-23-055533 · doc4.xml · derivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,946 Underlying: Common Stock · 34,946 shares Expires 2033-11-14 F3 · derivative.exercise_date: This option was granted on November 15, 2023. The shares underlying the option are scheduled to vest over four years in equal monthly installments through November 15, 2027. Read SEC document |
| November 15, 2023 Filed Nov 16, 2023 21:35 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 89,742 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-055533 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,537 F1 · shares: Consists of shares of Common Stock issuable under 89,742 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on February 15, 2024. F2 · balance_after: Includes 127,193 unvested RSUs. Read SEC document |
| September 18, 2023 Filed Sep 20, 2023 20:49 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,290 | $9.41 | $12,138.90 |
DisclosureSEC source: 0001209191-23-050174 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,795 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 37,451 unvested RSUs. Read SEC document |
| September 12, 2023 Filed Sep 13, 2023 23:53 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,397 | $10.41 | $14,542.77 |
DisclosureSEC source: 0001209191-23-049361 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,085 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $10.07 to $10.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3 · balance_after: Includes 40,317 unvested RSUs. Read SEC document |
| June 15, 2023 Filed Jun 15, 2023 21:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 10,000 | $12.03 | $120,300.00 |
DisclosureSEC source: 0001209191-23-037487 · doc4.xml · nonDerivative · entry 4 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,482 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.00 to $12.16, inclusive. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-23-037487 · doc4.xml · derivative · entry 5 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,740 Underlying: Common Stock · 40,000 shares Expires 2030-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The option was granted on January 6, 2020. The shares underlying the option vest over four years, with 25% of the shares vesting on December 2, 2020 and the remaining shares vesting in equal quarterly installments thereafter. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 40,000 | $12.89 | $515,600.00 |
DisclosureSEC source: 0001209191-23-037487 · doc4.xml · nonDerivative · entry 3 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,482 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $12.75 to $13.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) of this Form 4. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Exercise / conversionCommon Stock | 40,000 | $1.03 | $41,200.00 |
DisclosureSEC source: 0001209191-23-037487 · doc4.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:46 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,390 | $12.43 | $17,277.70 |
DisclosureSEC source: 0001209191-23-037487 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,482 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 43,297 unvested RSUs. Read SEC document |
| March 14, 2023 Filed Mar 15, 2023 21:51 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 1,311 | $13.33 | $17,475.63 |
DisclosureSEC source: 0001209191-23-018982 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,872 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021 and December 9, 2022. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 46,277 unvested RSUs. Read SEC document |
| December 12, 2022 Filed Dec 13, 2022 22:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 312 | $10.87 | $3,391.44 |
DisclosureSEC source: 0001209191-22-060975 · doc4.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,183 F3 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · balance_after: Includes 49,257 unvested RSUs. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $10.72 | $0.00 |
DisclosureSEC source: 0001209191-22-060975 · doc4.xml · derivative · entry 3 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2032-12-08 F5 · derivative.exercise_date: This option was granted on December 9, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2026. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 22:06 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 31,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-060975 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,495 F1 · shares: Consists of shares of Common Stock issuable under 31,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2023. F2 · balance_after: Includes 50,300 unvested RSUs. Read SEC document |
| September 20, 2022 Filed Sep 21, 2022 20:09 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 840 | $13.70 | $11,508.00 |
DisclosureSEC source: 0001209191-22-050893 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,495 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $13.70 to $13.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 19,300 unvested RSUs. Read SEC document |
| September 15, 2022 Filed Sep 15, 2022 21:30 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 326 | $14.05 | $4,580.30 |
DisclosureSEC source: 0001209191-22-050127 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,335 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 15, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $14.05 to $14.17, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 22,166 unvested RSUs. Read SEC document |
| July 11, 2022 Filed Jul 13, 2022 20:38 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $8.58 | $0.00 |
DisclosureSEC source: 0001209191-22-042058 · doc4.xml · derivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-07-10 F1 · derivative.exercise_date: This option was granted on July 11, 2022. The shares underlying the option are scheduled to vest over four years in equal monthly installments from July 1, 2022. Read SEC document |
| July 05, 2022 Filed Jul 6, 2022 22:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 17,333 | $0.00 Strike: $5.54 | $0.00 |
DisclosureSEC source: 0001209191-22-041342 · doc4.xml · derivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,333 Underlying: Common Stock · 17,333 shares Expires 2030-07-30 F1 · derivative.exercise_date: The option was granted on July 31, 2020, with 100% of the option to vest upon the clearance date of an Investigational New Drug (IND) application submitted to the U.S. Food and Drug Administration (FDA) by the Company with respect to one of its product candidates. On July 5, 2022, in connection with the clearance by the FDA of the Company's IND application for DYNE-251, the Compensation Committee determined that the performance condition had been achieved. Read SEC document |
| June 14, 2022 Filed Jun 16, 2022 00:05 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | Disposition to issuerCommon Stock | 333 | $4.95 | $1,648.35 |
DisclosureSEC source: 0001209191-22-037153 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,661 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 23,209 unvested RSUs. Read SEC document |
| March 11, 2022 Filed Mar 14, 2022 21:09 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 308 | $8.73 | $2,688.84 |
DisclosureSEC source: 0001209191-22-018537 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,994 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 10, 2021. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on March 11, 2022 to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $8.65 to $8.73, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in this footnote of this Form 4. F3 · balance_after: Includes 24,252 unvested RSUs. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 25,044 | $0.00 Strike: $13.12 | $0.00 |
DisclosureSEC source: 0001209191-21-069428 · doc4.xml · derivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,044 Underlying: Common Stock · 25,044 shares Expires 2031-12-09 F3 · derivative.exercise_date: This option was granted on December 10, 2021. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 10, 2025. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 21:23 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 16,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069428 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,302 F1 · shares: Consists of shares of Common Stock issuable under 16,696 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 10, 2022. F2 · balance_after: Includes 25,295 unvested RSUs. Each unvested RSU represents the right to receive one share of Common Stock upon vesting. Read SEC document |
| September 21, 2021 Filed Sep 23, 2021 00:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 492 | $16.11 | $7,926.12 |
DisclosureSEC source: 0001209191-21-057326 · doc4.xml · nonDerivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,606 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F4 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 21, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.87 to $16.36, inclusive. F3 · balance_after: Includes 8,599 unvested RSUs. Read SEC document |
| September 20, 2021 Filed Sep 23, 2021 00:03 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | SaleCommon Stock | 367 | $15.61 | $5,728.87 |
DisclosureSEC source: 0001209191-21-057326 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,098 F1 · shares: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on September 17, 2020. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price that represents the price of all shares sold by a broker on September 20, 2021 on behalf of a group of employees of the issuer to satisfy tax withholding obligations. These shares were sold in multiple transactions at prices within the range of $15.22 to $16.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in footnote (2) and (4) of this Form 4. F3 · balance_after: Includes 8,599 unvested RSUs. Read SEC document |
| September 17, 2020 Filed Sep 18, 2020 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantCommon Stock | 11,465 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025735 · doc4.xml · nonDerivative · entry 1 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,465 F1 · shares: Consists of shares of Common Stock issuable under 11,465 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal annual installments over four years with the first installment vesting on September 17, 2021. Read SEC document |
| September 16, 2020 Filed Sep 18, 2020 21:10 UTC | Dyne Therapeutics, Inc. DYN · Entity 3948 | GrantStock Option (right to buy) · Derivative | 35,575 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0000899243-20-025735 · doc4.xml · derivative · entry 2 Scalzo Richard William · CIK 0001789545 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,575 Underlying: Common Stock · 35,575 shares Expires 2030-09-15 F2 · derivative.exercise_date: This option was granted on September 16, 2020. The shares underlying the option are scheduled to vest over four years in equal monthly installments through September 16, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.